Cantor Fitzgerald’s Aspire Biopharma ASBP Stock Holding History

Cantor Fitzgerald’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-417	Closed	-$5.25M	–	676
2023 Q1	$5.25M	Hold	417	–	–	0.11%	238
2022 Q4	$5.15M	Hold	417	–	–	0.11%	233
2022 Q3	$5.07M	Hold	417	–	–	0.11%	224
2022 Q2	$4.99M	Buy	+417	New	+$4.99M	0.1%	241

Other funds holding ASBP

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Cantor Fitzgerald's ASBP Position: Q2 2023 in Review

Cantor Fitzgerald sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 417 shares — an estimated $5.25M sold.

Cantor Fitzgerald first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $5.25M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

Cantor Fitzgerald reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
Cantor Fitzgerald sold 417 Aspire Biopharma shares in Q2 2023, an estimated $5.25M.
Cantor Fitzgerald first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
Cantor Fitzgerald's Aspire Biopharma position peaked at $5.25M in Q1 2023.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Cantor Fitzgerald's 13F filing for Q2 2023, filed 14 Aug 2023.